drugset / Trial / NCT05636306
A Phase 1 Study to Evaluate Safety and Tolerability of NoNO-42 in Healthy Adults
RandomizedParallel-groupQuadruple-blindOther
Summary
The purpose of this clinical trial is to evaluate the safety, tolerability and pharmacokinetics of a single ascending intravenous dose of NoNO-42 administered to healthy adults. Participants will be administered a single intravenous dose of NoNO-42 or placebo. Participants will be confined for 24 hours post dose with a follow-up visit at Day 4 and Day 28.
Timeline
- Start
- 2022-11-22
- Primary completion
- 2023-10-05
- Completion
- 2023-10-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NoNO-42 | Unknown | — | Intravenous |
Indications
No indication recorded.